Uy Ear
Stock Analyst at Mizuho
(0)
# 2683
Out of 5,311 analysts
67
Total ratings
26.92%
Success rate
4.31%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
ARQT Arcutis Biotherapeut... | Maintains: Outperform | 20 21 | 12.22 | 71.85% | 14 | Feb 26, 2025 | |
QURE uniQure | Maintains: Neutral | 7 20 | 8.52 | 134.74% | 4 | Dec 19, 2024 | |
RLMD Relmada Therapeutics | Downgrades: Neutral | 23 1 | 0.28 | 257.14% | 1 | Dec 5, 2024 | |
ALKS Alkermes | Maintains: Outperform | 35 40 | 26.43 | 51.34% | 5 | Nov 13, 2024 | |
SAGE Sage Therapeutics | Maintains: Neutral | 18 16 | 6.89 | 132.22% | 2 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 40 | 10.46 | 282.41% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 145 179 | 50.25 | 256.22% | 5 | May 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 25 21 | 13.98 | 50.21% | 10 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 20 23 | 9.37 | 145.46% | 3 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 116 140 | 90.06 | 55.45% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 60 24 | n/a | n/a | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 35 16 | n/a | n/a | 1 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 4 3 | n/a | n/a | 2 | Aug 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 36 40 | 149.33 | -73.21% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 2 | n/a | n/a | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 10 | 1.14 | 777.19% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 5 3 | 0.7 | 328.57% | 2 | Mar 1, 2023 |